SION SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 2, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Sionna Therapeutics to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Trial and Announces Workforce Reduction

Sep 14, 2026

8-K

Sionna Therapeutics Reports Topline Data from Cystic Fibrosis Programs and Provides Corporate Update

Aug 10, 2026

8-K

Sionna Therapeutics Reports Second Quarter 2026 Financial Results and Pipeline Progress

Aug 6, 2026

8-K

Sionna Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 18, 2026

8-K

Sionna Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress

May 12, 2026

8-K

Sionna Therapeutics Reports Q4 and Full Year 2025 Results, Anticipates Mid-2026 Data Readouts for Key CF Trials

Mar 2, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

SHARE RESALE REGISTRATION | Shares amount: 10,588,233 | Share price: $18 | Offering amount: $190,588,194

Feb 7, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 2, 2026

S-3ASR

March 2026 SHELF + ATM

Mar 2, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 7, 2025

S-1MEF

SHARE RESALE REGISTRATION | Shares amount: 2,029,409

Feb 6, 2025

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Feb 4, 2025

S-1/A

SHARE RESALE REGISTRATION | Shares amount: 8,823,529 | Share price: $17

Feb 3, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 27, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

NEWGOLDMAN SACHS GROUP INC (Filed by)

Nov 9, 2026

SCHEDULE 13D/A

RA CAPITAL MANAGEMENT, L.P. (Filed by)

Sep 21, 2026

RA Capital Healthcare Fund LP (Reporting)

Sep 21, 2026

Ridloff Elena (Reporting)

Sep 18, 2026

McKee Charlotte (Reporting)

Sep 18, 2026

Fitzpatrick Jennifer (Reporting)

Sep 18, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 7, 2025

CORRESP

Form CORRESP - Correspondence

Feb 4, 2025

CORRESP

Form CORRESP - Correspondence

Feb 4, 2025

CORRESP

Form CORRESP - Correspondence

Jan 24, 2025

CORRESP

Form CORRESP - Correspondence

Jan 17, 2025

LETTER

Form UPLOAD - SEC-generated letter

Dec 10, 2024

Sionna Therapeutics, Inc. SION · SEC Filings